Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EEF2K | O00418 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.34 |
| ▸ | MTOR | P42345 | 9/20 | 0.33 |
| ▸ | PDE5A | O76074 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
| ▸ | EEF2 | P13639 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL874071 | 0.84 | EEF2K (0.36) | EEF2KPIK3CAMTORPDE5APDE4A | |
| SCHEMBL872488 | 0.83 | PDE5A (0.46) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL872848 | 0.81 | ADORA2A (0.36) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL871896 | 0.80 | TSHR (0.37) | EEF2KPIK3CAMTORPDE5APDE4A | |
| SCHEMBL15261253 | 0.77 | PIK3CA (0.31) | PIK3CA | |
| SCHEMBL872452 | 0.77 | ADA (0.42) | PIK3CAMTOR | |
| SCHEMBL872376 | 0.76 | ALDH1A1 (0.36) | MTORPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17066864 | 0.76 | NR1I2 (0.30) | PDE4D | |
| SCHEMBL17066830 | 0.75 | PIK3CA (0.32) | PIK3CAPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL28805232 | 0.74 | PIK3CA (0.35) | EEF2KPIK3CAMTORAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619211-B1 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS LTD (IN) | 2015-09-09 | — | — | EP | disclosed |
| US-9006177-B2 | Fused tricyclic compounds as adenosine receptor antagonist | ADVINUS THERAPEUTICS LIMITED (IN) | 2015-04-14 | — | — | US | disclosed |
| US-9006177-B2 | Fused tricyclic compounds as adenosine receptor antagonist | ADVINUS THERAPEUTICS LIMITED (IN) | 2015-04-14 | — | — | US | disclosed |
| US-9006177-B2 | Fused tricyclic compounds as adenosine receptor antagonist | ADVINUS THERAPEUTICS LIMITED (IN) | 2015-04-14 | — | — | US | disclosed |
| US-20130252885-A1 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-09-26 | — | — | US | disclosed |
| US-20130252885-A1 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-09-26 | — | — | US | disclosed |
| US-20130252885-A1 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-09-26 | — | — | US | disclosed |
| EP-2619211-A2 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | Advinus Therapeutics Private Limited (IN) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012038980-A2 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252885-A1 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADORA2A, ADORA2B, ADORA1 | EEF2K 2179/4885PIK3CA 194/4885MTOR 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.